The new chief executive of dual-listed cancer diagnostics company Pacific Edge has set out three major areas of growth for the firm following a challenging second half for the company.
Pacific Edge today reported a 33% increase in its total revenue to $13.9 million for the year ended March 31, 2022.
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
